ZEALAND PHARMA/S (ZEAL) Sets New 1-Year High at $20.85

ZEALAND PHARMA/S (NASDAQ:ZEAL) shares reached a new 52-week high during trading on Tuesday . The stock traded as high as $20.85 and last traded at $20.64, with a volume of 931 shares. The stock had previously closed at $19.70.

A number of research analysts have recently issued reports on the company. TheStreet upgraded ZEALAND PHARMA/S from a “d+” rating to a “c-” rating in a report on Tuesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $29.00 price target on shares of ZEALAND PHARMA/S in a report on Thursday, March 7th. ValuEngine upgraded ZEALAND PHARMA/S from a “sell” rating to a “hold” rating in a report on Friday, March 15th. Finally, Zacks Investment Research downgraded ZEALAND PHARMA/S from a “buy” rating to a “hold” rating and set a $21.00 price target on the stock. in a report on Saturday, April 13th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $26.00.

The firm has a market cap of $628.36 million, a PE ratio of 6.80 and a beta of 2.40.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.08. The company had revenue of $2.01 million during the quarter. On average, equities research analysts expect that ZEALAND PHARMA/S will post -1.68 earnings per share for the current fiscal year.

A hedge fund recently bought a new stake in ZEALAND PHARMA/S stock. OLD Mission Capital LLC bought a new position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 17,466 shares of the company’s stock, valued at approximately $203,000. OLD Mission Capital LLC owned about 0.06% of ZEALAND PHARMA/S at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2019/05/16/zealand-pharma-s-zeal-sets-new-1-year-high-at-20-85.html.


Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Recommended Story: How Do I Invest in Dividend Stocks

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with MarketBeat.com's FREE daily email newsletter.